Cart
0

Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, and Octreotide) and Application (Gastric & Digestive Disorders, Bone Diseases, Diabetes, and Hormonal Disorders): Global Opportunity Analysis and Industry Forecast, 2017-2028

Get 20% Free Customization In This Report
LI_18378
Pages: 120
Mar 2018 | 3446 Views
 
Author's : Sohail Shaikh & Pallavi Jaiswal
Tables: 29
Charts: 36
 

Oral Proteins and Peptides Market Overview:

Proteins and Peptides are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases, which can be administered orally are known as oral peptide and protein-based drugs. The global oral proteins and peptides market accounted for $643 million in 2016, and is anticipated to reach $8,233 million by 2028, registering a CAGR of 11.7% from 2022 to 2028.

The demand for oral peptide and protein-based therapeutics has increased significantly, owing to increase in prevalence of chronic diseases, rise in patient preference for oral drugs, and enhanced patient compliance. Furthermore, surge in elderly population along with improvement in healthcare settings boost the market. However, high costs associated with oral peptides and proteins and low bioavailability of these drugs in the body restrict the growth of the market. Furthermore, increase in R&D by pharmaceutical companies and surge in purchasing power of emerging economies provide lucrative opportunities to the market players.

Get more information on this report : Request Sample Pages

The oral proteins and peptides market is segmented into drug type, application, and region. By drug type, the market is divided into linaclotide, plecanatide, calcitonin, insulin, and octreotide. By application, the oral proteins and peptides market is categorized into gastric & digestive disorders, bone diseases, diabetes, and hormonal disorders. Based on region, the oral proteins and peptides market is analyzed across U.S. and rest of the world.

Get more information on this report : Request Sample Pages

The U.S. is anticipated to generate the highest revenue in the oral proteins and peptides market in 2022. The rest of the world possesses high market potential for the growth of the market, owing to increase in awareness about oral peptide and protein therapeutics based treatment and rise in oral peptide and protein therapeutics applications. This region is anticipated to experience fast-paced growth, in terms of development and use of protein therapeutics.

Get more information on this report : Request Sample Pages

The diabetes application is anticipated to occupy the largest share in the oral proteins and peptides market in 2022 owing to the high adoption of oral insulin, surge in geriatric population, and rise in prevalence of diabetes.

Get more information on this report : Request Sample Pages

The report provides extensive competitive analysis and profiles of key market players, such as Allergan plc, AstraZeneca plc, Biocon Limited, Chiasma, Inc., Proxima Concepts Limited (Diabetology Ltd.), Generex Biotechnology Corp., Novo Nordisk A/S, Synergy Pharmaceuticals Inc., and Tarsa Therapeutics Inc. Other players (profiles not included in the report) in the value chain analysis include Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics, Inc., Hovione Limited, and Novartis International AG.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2028 to identify the prevailing opportunities.
  • The oral proteins and peptides market size and market estimations are based on comprehensive analysis of the key developments in the industry.
  • In-depth analysis based on region elucidates the regional market and the strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Oral Proteins and Peptides Market Key Segments:

By Drug Type

  • Linaclotide
  • Plecanatide
  • Calcitonin
  • Insulin
  • Octreotide

By Application

  • Gastric & Digestive Disorders
  • Bone Diseases
  • Diabetes
  • Hormonal Disorders

By Region

  • U.S.
  • Rest of the world
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. Key findings of the study

2.1.1. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Clinical trials
3.4. Top player positioning, 2018
3.5. Patent analysis, 2010-2017

3.5.1. Patent analysis, by year (2010-2017)
3.5.2. Patent analysis, by country

3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in collaboration between pharmaceutical companies for drug development
3.6.1.2. Surge in prevalence of chronic diseases
3.6.1.3. Rise in geriatric population and improvement in healthcare infrastructure

3.6.2. Restraints

3.6.2.1. Low bioavailability of oral proteins and peptides
3.6.2.2. High costs associated with drug development

3.6.3. Opportunities

3.6.3.1. Increase in purchasing power of emerging economics
3.6.3.2. Increase in R&D activities by pharmaceutical companies

Chapter: 4: ORAL PROTEINS AND PEPTIDES MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Linaclotide

4.2.1. Key market trends
4.2.2. Market size and forecast

4.3. Plecanatide

4.3.1. Key market trends
4.3.2. Market size and forecast

4.4. Calcitonin

4.4.1. Key market trends
4.4.2. Market size and forecast

4.5. Insulin

4.5.1. Key market trends
4.5.2. Market size and forecast

4.6. Octreotide

4.6.1. Key market trends
4.6.2. Market size and forecast

Chapter: 5: ORAL PROTEINS AND PEPTIDES MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Gastric & digestive disorders

5.2.1. Market size and forecast

5.3. Bone diseases

5.3.1. Market size and forecast

5.4. Diabetes

5.4.1. Market size and forecast

5.5. Hormonal disorders

5.5.1. Market size and forecast

Chapter: 6: ORAL PROTEINS AND PEPTIDES MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. U.S.

6.2.1. Key market trends
6.2.2. Market size and forecast

6.3. Rest of the world

6.3.1. Key market trends
6.3.2. Market size and forecast

Chapter: 7: COMPANY PROFILES

7.1. Allergan Plc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AstraZeneca PLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. Biocon Limited

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. Chiasma Inc.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Product portfolio
7.4.4. Key strategic moves and developments

7.5. Generex Biotechnology Corp.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments

7.6. Novo Nordisk A/S

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Oramed Pharmaceuticals Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Product portfolio
7.7.4. Key strategic moves and developments

7.8. Proxima Concepts Limited (Diabetology Ltd.)

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio

7.9. Synergy Pharmaceuticals Inc.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Key strategic moves and developments

7.10. Tarsa Therapeutics Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Product portfolio
7.10.4. Key strategic moves and developments

LIST OF TABLES

TABLE 01. COMPLETED CLINICAL TRIALS IN ORAL PROTEIN AND PEPTIDES MARKET
TABLE 02. GLOBAL ORAL PROTEINS AND PEPTIDES MARKET, BY DRUG TYPE, 2016-2023 ($MILLION)
TABLE 03. GLOBAL ORAL PROTEINS AND PEPTIDES MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 04. ORAL PROTEINS AND PEPTIDES MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. ALLERGAN: COMPANY SNAPSHOT
TABLE 06. ALLERGAN: OPERATING SEGMENTS
TABLE 07. ALLERGAN: PRODUCT PORTFOLIO
TABLE 08. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 09. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 10. BIOCON: COMPANY SNAPSHOT
TABLE 11. BIOCON: OPERATING SEGMENTS
TABLE 12. BIOCON: PRODUCT PORTFOLIO
TABLE 13. CHIASMA: COMPANY SNAPSHOT
TABLE 14. CHIASMA: PRODUCT PORTFOLIO
TABLE 15. GENEREX: COMPANY SNAPSHOT
TABLE 16. GENEREX: OPERATING SEGMENTS
TABLE 17. GENEREX: PRODUCT PORTFOLIO
TABLE 18. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 19. NOVO NORDISK: OPERATING SEGMENTS
TABLE 20. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 21. ORAMED: COMPANY SNAPSHOT
TABLE 22. ORAMED: PRODUCT PORTFOLIO
TABLE 23. PROXIMA CONCEPTS: COMPANY SNAPSHOT
TABLE 24. PROXIMA CONCEPTS: OPERATING SEGMENTS
TABLE 25. PROXIMA CONCEPTS: PRODUCT PORTFOLIO
TABLE 26. SYNERGY: COMPANY SNAPSHOT
TABLE 27. SYNERGY: PRODUCT PORTFOLIO
TABLE 28. TARSA: COMPANY SNAPSHOT
TABLE 29. TARSA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS, 2028
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015-2018*
FIGURE 06. TOP PLAYER POSITIONING, 2018
FIGURE 07. PATENT REGISTERED/APPROVED, BY YEAR
FIGURE 08. PATENT REGISTERED, BY COUNTRY
FIGURE 09. ORAL PROTEINS AND PEPTIDES MARKET: IMPACT ANALYSES
FIGURE 10. DIABETES BURDEN: KEY TAKEAWAYS, 2014
FIGURE 11. GLOBAL ELDERLY POPULATION (AGED 65 AND ABOVE), BY REGION (2015, 2030, AND 2050)
FIGURE 12. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION, BY DRUG TYPE
FIGURE 13. ORAL PROTEINS AND PEPTIDES MARKET FOR LINACLOTIDE, 2016-2028 ($MILLION)
FIGURE 14. ORAL PROTEINS AND PEPTIDES MARKET FOR PLECANATIDE, 2017-2028 ($MILLION)
FIGURE 15. ORAL PROTEINS AND PEPTIDES MARKET FOR CALCITONIN, 2020-2028 ($MILLION)
FIGURE 16. ORAL PROTEINS AND PEPTIDES MARKET FOR INSULIN, 2020-2028 ($MILLION)
FIGURE 17. ORAL PROTEINS AND PEPTIDES MARKET FOR OCTREOTIDE, 2022-2028 ($MILLION)
FIGURE 18. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION, BY APPLICATION
FIGURE 19. ORAL PROTEINS AND PEPTIDES MARKET FOR GASTRIC & DIGESTIVE DISORDERS, 2016-2028 ($MILLION)
FIGURE 20. ORAL PROTEINS AND PEPTIDES MARKET FOR BONE DISEASES, 2017-2028 ($MILLION)
FIGURE 21. ORAL PROTEINS AND PEPTIDES MARKET FOR DIABETES, 2020-2028 ($MILLION)
FIGURE 22. ORAL PROTEINS AND PEPTIDES MARKET FOR HORMONAL DISORDERS, 2022-2028 ($MILLION)
FIGURE 23. ORAL PROTEINS AND PEPTIDES MARKET SEGMENTATION, BY REGION
FIGURE 24. U.S. ORAL PROTEINS AND PEPTIDES MARKET, 2016-2028 ($MILLION)
FIGURE 25. REST OF THE WORLD ORAL PROTEINS AND PEPTIDES MARKET, 2017-2028 ($MILLION)
FIGURE 26. ALLERGAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 27. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 28. ASTRAZENECA: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. ASTRAZENECA: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 30. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 31. BIOCON: NET SALES, 2015-2017 ($MILLION)
FIGURE 32. BIOCON: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 33. BIOCON: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 34. NOVO NORDISK: NET SALES, 2015-2017 ($MILLION)
FIGURE 35. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 36. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

Oral proteins and peptide-based drugs contributed significantly in treatment of chronic diseases such as irritable bowel syndrome (IBS) in 2017. Furthermore, advanced oral proteins and peptides are being studied to treat diseases such as diabetes, post-menopausal osteoporosis, and others. These drugs are expected to witness high adoption rate during the forecast period due to surge in prevalence of chronic diseases and increase in elderly population.

However, high costs associated with oral proteins and peptide drug development and low bioavailability of these drugs in the body restrict the market growth. At present, gastric & digestive disorder treatment through oral proteins and peptide-based drugs holds a maximum share in the global market, and is expected to maintain this trend during the study period. This is attributed to rise in prevalence of chronic diseases such as IBS among the geriatric population.

Increase in awareness toward oral proteins & peptide-based drugs and investment in research, innovation, and drug development fuel the demand for oral proteins and peptides. The employment of these is highest in the U.S., owing to increase in adoption of these drugs, followed by the rest of the world.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Oral Proteins and Peptides Market

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo